Attreyi Mukherjee

Part of Tata Chemicals Ltd., Impetis Biosciences Ltd. is an IP focused drug discovery and licensing company founded in 2017. Impetis is headquartered in Mumbai, India, and seeks to license its assets to pharma companies for further development. The Indian company has developed therapeutic assets for autoimmune and inflammatory diseases, immuno-oncology, and Nonalcoholic steatohepatitis (NASH). The company's therapeutic assets include Receptor Activator (GRA), Bruton's Tyrosine Kinase Inhibitors (BTKi), ROR?t Inhibitor Program, GPR91 antagonists, and Adenosine receptor antagonists. The Board of Directors includes Mr. KRS Jamwal (Executive Director, Tata Industries), Mr. S. Sriram (CFO and Company Secretary, Tata Industries), and Attreyi Mukherjee (Senior Corporate Counsel, Tata Industries Ltd. & Director, Impetis Biosciences).